

# Roberta Di Blasi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1917289/publications.pdf>

Version: 2024-02-01

7  
papers

376  
citations

1307594

7  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

662  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 5607-5615.	5.2	222
2	Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). <i>Haematologica</i> , 2015, 100, 284-292.	3.5	64
3	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. <i>Blood Advances</i> , 2022, 6, 2427-2433.	5.2	46
4	Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM registry. <i>British Journal of Haematology</i> , 2015, 170, 434-439.	2.5	14
5	Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 4657-4660.	5.2	11
6	Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). <i>Annals of Hematology</i> , 2018, 97, 791-798.	1.8	10
7	Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. <i>Neurology</i> , 2022, 99, 511-515.	1.1	9